Trial Profile

A Multi-center, Open-label, Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CM 336 (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors KeyMed Biosciences

Most Recent Events

26 Mar 2025 According to KeyMed Biosciences media release, as of the date, company continuously proceeded and the CM-336 is currently in the dose-expansion phase of Phase I/II clinical study.
04 Apr 2022 According to KeyMed Biosciences media release, CM336 has been approved by the National Medical Products Administration (NMPA) for the treatment of relapsed or refractory patients.
01 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com